Flocculated amorphous itraconazole nanoparticles for enhanced in vitro supersaturation and in vivo bioavailability

Drug Development and Industrial Pharmacy

Volumn 38, Issue 5, 2012, Pages 557-570

  Miller, Maria A ^a   DiNunzio, James ^b   Matteucci, Michal E ^a   Ludher, Baltej S ^a   Williams, Robert O ^b   Johnston, Keith P ^a  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Amorphous drug; nanoparticle filtration; nanoparticle recovery; pH shift dissolution; stabilization of supersaturation

Indexed keywords

EUDRAGIT; HYDROXYPROPYLMETHYLCELLULOSE; ITRACONAZOLE; NANOPARTICLE; POLYMER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; FLOCCULATION; IN VITRO STUDY; IN VIVO STUDY; MICELLE; NONHUMAN; PH; PRECIPITATION; RAT; SIMULATION;

ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; FLOCCULATION; HYDROGEN-ION CONCENTRATION; ITRACONAZOLE; METHYLCELLULOSE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SOLUTIONS;

EID: 84859296895     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.616513     Document Type: Article

References (59)

1. Chen H, Wan J, Wang Y, Mou D, Liu H, Xu H, Yang X. (2008). A facile nanoaggregation strategy for oral delivery of hydrophobic drugs by utilizing acid-base neutralization reactions. Nanotechnology, 19:375104.
2. Fahr A, Liu X. (2007). Drug delivery strategies for poorly watersoluble drugs. Expert Opin Drug Deliv, 4:403-416. (Pubitemid 47249138)
3. Lipinski C. (2004). Solubility in the design of combinatorial libraries. In: Yan B (ed.) Analysis and Purification Methods in Combinatorial Chemisty. Hoboken, NJ: John Wiley & Sons, Inc.
4. Gupta P, Chawla G, Bansal AK. (2004). Physical stability and solubility advantage from amorphous celecoxib: the role of thermodynamic quantities and molecular mobility. Mol Pharm, 1:406-413.
5. Matteucci ME, Miller MA, Williams RO, Johnston KP. (2008). Highly supersaturated solutions of amorphous drugs approaching predictions from configurational thermodynamic properties. J Phys Chem B, 112:16675-16681.
6. Parks GS, Snyder LJ, Cattoir FR. (1934). Studies on glass. XI. Some thermodynamic relations of glassy and alpha-crystalline glucose. J Chem Phys, 2:595-598.
7. Hancock BC, Parks M. (2000). What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res, 17:397-404. (Pubitemid 30395293)
8. Lindfors L, Skantze P, Skantze U, Westergren J, Olsson U. (2007). Amorphous drug nanosuspensions. 3. Particle dissolution and crystal growth. Langmuir, 23:9866-9874.
9. Matteucci ME, Brettmann BK, Rogers TL, Elder EJ, Williams RO, Johnston KP. (2007). Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media. Mol Pharm, 4:782-793. (Pubitemid 350004278)
10. Pan X, Julian T, Augsburger L. (2008). Increasing the dissolution rate of a low-solubility drug through a crystalline-amorphous transition: a case study with indomethacin [correction of indomethicin]. Drug Dev Ind Pharm, 34:221-231. (Pubitemid 351317152)
11. Yamada T, Saito N, Imai T, Otagiri M. (1999). Effect of grinding with hydroxypropyl cellulose on the dissolution and particle size of a poorly water-soluble drug. Chem Pharm Bull, 47:1311-1313. (Pubitemid 29484889)
12. Hasegawa A, Kawamura R, Nakagawa H, Sugimoto I. (1985). Physical properties of solid dispersions of poorly water-soluble drugs with enteric coating agents. Chem Pharm Bull, 33:3429-3435. (Pubitemid 16221865)
13. Okimoto K, Miyake M, Ibuki R, Yasumura M, Ohnishi N, Nakai T. (1997). Int J Pharm, 159:85-93.
14. Palanisamy M, Khanam J. (2011). Solid dispersion of prednisolone: solid state characterization and improvement of dissolution profile. Drug Dev Ind Pharm, 37:373-386.
15. Suzuki H, Sunada H. (1997). Comparison of nicotinamide, ethylurea and polyethylene glycol as carriers for nifedipine solid dispersion systems. Chem Pharm Bull, 45:1688-1693. (Pubitemid 27488434)
16. Yamashita K, Nakate T, Okimoto K, Ohike A, Tokunaga Y, Ibuki R et al. (2003). Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm, 267:79-91. (Pubitemid 37352952)
17. Aitken-Nichol C, Zhang F, McGinity JW. (1996). Hot melt extrusion of acrylic films. Pharm Res, 13:804-808. (Pubitemid 26160100)
18. Zhu Y, Shah NH, Malick AW, Infeld MH, McGinity JW. (2006). Controlled release of a poorly water-soluble drug from hot-melt extrudates containing acrylic polymers. Drug Dev Ind Pharm, 32:569-583. (Pubitemid 43982407)
19. Leuner C, Dressman J. (2000). Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm, 50:47-60. (Pubitemid 30326688)
20. Six K, Berghmans H, Leuner C, Dressman J, Van Werde K, Mullens J et al. (2003). Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion, Part II. Pharm Res, 20:1047-1054. (Pubitemid 36774276)
21. Six K, Verreck G, Peeters J, Brewster M, Van Den Mooter G. (2004). Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers. J Pharm Sci, 93:124-131. (Pubitemid 38081820)
22. Suzuki H, Sunada H. (1998). Influence of water-soluble polymers on the dissolution of nifedipine solid dispersions with combined carriers. Chem Pharm Bull, 46:482-487. (Pubitemid 28188567)
23. Verreck G, Six K, Van den Mooter G, Baert L, Peeters J, Brewster ME. (2003). Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion-Part I. Int J Pharm, 251:165-174. (Pubitemid 36071471)
24. Matteucci ME, Paguio JC, Miller MA, Williams RO, Johnston KP. (2008). Flocculated amorphous nanoparticles for highly supersaturated solutions. Pharm Res, 25:2477-2487.
25. DiNunzio JC, Hughey JR, Brough C, Miller DA, Williams RO, McGinity JW. (2010). Production of advanced solid dispersions for enhanced bioavailability of itraconazole using KinetiSol Dispersing. Drug Dev Ind Pharm, 36:1064-1078.
26. DiNunzio JC, Miller DA, Yang W, McGinity JW, Williams RO. (2008). Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole. Mol Pharm, 5:968-980.
27. Matteucci ME, Paguio JC, Miller MA, Williams RO, Johnston KP. (2009). Highly supersaturated solutions from dissolution of amorphous itraconazole microparticles at pH 6.8. Mol Pharm, 6:375-385.
28. Miller DA, DiNunzio JC, Yang W, McGinity JW, Williams RO . (2008). Enhanced in vivo absorption of itraconazole via stabilization of supersaturation following acidic-to-neutral pH transition. Drug Dev Ind Pharm, 34:890-902.
29. Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, Kuhn JG. (1988). Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother, 32:1310-1313.
30. Shin JH, Choi KY, Kim YC, Lee MG. (2004). Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. Antimicrob Agents Chemother, 48:1756-1762. (Pubitemid 38544385)
31. Jaruratanasirikul S, Kleepkaew A. (1997). Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol, 52:235-237. (Pubitemid 27278380)
32. Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, Srichai W. (2005). Reduced oral itraconazole bioavailability by antacid suspension. J Clin Pharm Ther, 30:201-206. (Pubitemid 41603042)
33. Miller DA, DiNunzio JC, Yang W, McGinity JW, Williams RO. (2008). Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption. Pharm Res, 25:1450-1459.
34. Brewster ME, Vandecruys R, Peeters J, Neeskens P, Verreck G, Loftsson T. (2008). Comparative interaction of 2-hydroxypropylbeta- cyclodextrin and sulfobutylether-beta-cyclodextrin with itraconazole: phase-solubility behavior and stabilization of supersaturated drug solutions. Eur J Pharm Sci, 34:94-103.
35. Chen X, Matteucci ME, Lo CY, Johnston KP, Williams RO. (2009). Flocculation of polymer stabilized nanocrystal suspensions to produce redispersible powders. Drug Dev Ind Pharm, 35:283-296.
36. Brewster ME, Neeskens P, Peeters J. (2007). Solubilization of itraconazole as a function of cyclodextrin structural space. J Incl Phenom Macrocycl Chem, 57:561-566.
37. Mithani SD, Bakatselou V, Tenhoor CN, Dressman JB. (1996). Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm Res, 13:163-167. (Pubitemid 26076314)
38. Wong J, Papadopoulos P, Werling J, Rebbeck C, Doty M, Kipp J, Konkel J, Neuberger D. (2006). Itraconazole suspension for intravenous injection: Determination of the real component of complete refractive index for particle sizing by static light scattering. PDA J Pharm Sci Technol, 60:302-313. (Pubitemid 44623355)
39. Bakatselou V, Oppenheim RC, Dressman JB. (1991). Solubilization and wetting effects of bile salts on the dissolution of steroids. Pharm Res, 8:1461-1469.
40. Dickson JL, Gupta G, Horozov TS, Binks BP, Johnston KP. (2006). Wetting phenomena at the CO2/water/glass interface. Langmuir, 22:2161-2170.
41. Alban L, Dahl AK, Hansen AK, Hejgaard KC, Jensen AL, Kragh M, Thomsen P, Stennsgaard P. (2001). The welfare impact of increased gavaging doses in rats. Anim Welfare, 10, 303-314. (Pubitemid 33674889)
42. Gubbins PO, Gurley BJ, Bowman J. (1998). Rapid and sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum. J Pharm Biomed Anal, 16:1005-1012. (Pubitemid 28139037)
43. Vaughn JM, McConville JT, Burgess D, Peters JI, Johnston KP, Talbert RL et al. (2006). Single dose and multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm, 63:95-102. (Pubitemid 43776206)
44. Hiemenz PC, Rajagopalan R. (1997). Principles of Colloid and Surface Chemistry, New York, Marcel Dekker, Inc.
45. Shi L, Berkland C. (2006). pH-triggered dispersion of nanoparticle clusters. Adv Mater, 18:2315-2319. (Pubitemid 44433682)
46. Overhoff KA, Moreno A, Miller DA, Johnston KP, Williams RO. (2007). Solid dispersions of itraconazole and enteric polymers made by ultra-rapid freezing. Int J Pharm, 336:122-132. (Pubitemid 46551563)
47. Six K, Verreck G, Peeters J, Binnemans K, Berghmans H, Augustijns P, Kinget R, Van Den Mooter G. (2001). Investigation of thermal properties of glassy itraconazole: identification of a monotropic mesophase. Thermochim Acta, 376:175-181. (Pubitemid 32803453)
48. Petereit HU, Weisbrod W. (1999). Formulation and process considerations affecting the stability of solid dosage forms formulated with methacrylate copolymers. Eur J Pharm Biopharm, 47:15-25.
49. Miller DA, McConville JT, Yang W, Williams RO 3rd, McGinity JW. (2007). Hot-melt extrusion for enhanced delivery of drug particles. J Pharm Sci, 96:361-376. (Pubitemid 46363567)
50. Liu R, Sadrzadeh N & Constantinides PP. (2000). Micellization and drug solubility enhancement. In: Liu R (ed.) Water-Insoluble Drug Formation. Denver: Interpharm Press.
51. Hong JY, Kim JK, Song YK, Park JS, Kim CK. (2006). A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J Control Release, 110:332-338.
52. Zhang X, Tsang AM, Okino MS, Power FW, Knaak JB, Harrison LS et al. (2007). A physiologically based pharmacokinetic/ pharmacodynamic model for carbofuran in Sprague-Dawley rats using the exposure-related dose estimating model. Toxicol Sci, 100:345-359. (Pubitemid 350131362)
53. Jain A, Ran Y, Yalkowsky SH. (2004). Effect of pH-sodium lauryl sulfate combination on solubilization of PG-300995 (an anti-HIV agent): a technical note. AAPS PharmSciTech, 5:e45.
54. Naylor LJ, Bakatselou V, Dressman JB. (1993). Comparison of the mechanism of dissolution of hydrocortisone in simple and mixed micelle systems. Pharm Res, 10:865-870. (Pubitemid 23167569)
55. Schamp K, Schreder SA, Dressman J. (2006). Development of an in vitro/in vivo correlation for lipid formulations of EMD 50733, a poorly soluble, lipophilic drug substance. Eur J Pharm Biopharm, 62:227-234. (Pubitemid 43356569)
56. Six K, Daems T, de Hoon J, Van Hecken A, Depre M, Bouche MP et al. (2005). Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. Eur J Pharm Sci, 24:179-186. (Pubitemid 40127548)
57. Suzuki H, Ogawa M, Hironaka K, Ito K, Sunada H. (2001). A nifedipine coground mixture with sodium deoxycholate. II. Dissolution characteristics and stability. Drug Dev Ind Pharm, 27:951-958. (Pubitemid 33101455)
58. Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M et al. (2008). In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol. J Control Release, 130:29-37.
59. Crisp MT, Tucker CJ, Rogers TL, Williams RO, Johnston KP. (2007). Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals. J Control Release, 117:351-359. (Pubitemid 46216578)